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Abstract
Objective—This study assessed the relative cost-effectiveness of a first generation and a second 
generation long-acting injectable antipsychotic: haloperidol decanoate (HD) and paliperidone 
palmitate (PP), respectively.
Methods—A multisite, double-blind, randomized 18-month clinical trial conducted at 22 clinical 
research U.S. sites with adults diagnosed with schizophrenia or schizoaffective disorder (n=311) 
clinically assessed to benefit from a LAI antipsychotic. Patients were randomly assigned to 
Intramuscular injections of HD 25–200 mg or PP 39–234 mg every month for up to 24 months. 
Quality Adjusted Life Years was measured by a schizophrenia-specific algorithm based on the 
Positive and Negative Syndrome Scale and side effect assessments; and total health care costs 
from the perspective of the health system.
Results—Mixed model analysis of QALYs showed PP with .027 greater QALYs over 18 months 
(p=.03) but also greater average quarterly inpatient, outpatient and medication costs of $2,100/
quarter (p<.0001). Bootstrap analysis with 5,000 replications showed an Incremental Cost 
effectiveness ratio for PP of $508,241/QALY (95% CI of $122,390–$1,582,711). Net Health 
Benefits analysis showed a 0.98 probability of greater cost-effectiveness for HD over PP at an 
estimated valuation of health of $150,000/QALY and only 0.50 greater at $500,000/QALY.
Conclusions—HD was more cost-effective than PP suggesting that PP’s slightly greater benefits 
do not justify its markedly higher on-patent costs.
Non-adherence to prescribed medication is a major cause of relapse, re-hospitalization, and 
increased health care costs in the treatment of schizophrenia. (1) Long-acting injectable 
(LAI) antipsychotic medications, which can be administered every two to four weeks, are 
used to reduce non-adherence and relapse. The use of LAI versions of first generation 
antipsychotics has been limited in part due to concerns about the risk of extrapyramidal side 
effects. The second generation antipsychotic, risperidone microspheres was introduced in 
2003 but must be refrigerated before use, reconstituted with a diluent, and administered 
every two weeks. In 2009, paliperidone palmitate, a long-acting version of risperidone’s 
active metabolite became available. It can be administered monthly and does not require 
refrigeration or reconstitution. Because of these logistical advantages, paliperidone palmitate 
was considered to be an important advance in LAI antipsychotics (2), although its high cost 
left uncertainty about whether its costs are justified by greater benefits.
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Recent trials have raised some doubts about the clinical advantages of oral second 
generation antipsychotics (3–6). Some newer antipsychotics appear to cause significant 
metabolic problems (7) and randomized trials have failed to find advantages of LAI second 
generation antipsychotics as compared to oral antipsychotics (8, 9). However, one recent 
study found robust benefits for LAI as compared to oral risperidone (10) in first episode 
psychosis.
In view of these uncertainties, a randomized clinical trial was designed to compare LAI 
paliperidone palmitate (PP) and haloperidol decanoate (HD), and found no advantage for PP 
in preventing relapse but greater weight gain and reduced risk of akathisia (11). This study 
evaluates the cost-effectiveness of PP and HD to determine the relative effects of PP and HD 
using a measure of the health status of people diagnosed with schizophrenia that addresses 
both symptoms and side effects in a single measure, and whether any advantage of PP merits 
its greater cost.
Method
Study setting and design
A Comparison of Long-acting Injectable Medications for Schizophrenia (ACLAIMS) was a 
multisite, parallel-group, double-blinded randomized controlled trial (11) conducted at 22 
U.S. clinical sites from 2011–2013. Each site obtained institutional review board approval to 
conduct the study.
Patients
Patients were adults aged 18–65 with a diagnosis of schizophrenia or schizoaffective 
disorder confirmed by the Structured Clinical Interview for DSM-IV (SCID). Patients were 
eligible if judged by a referring psychiatrist as likely to benefit from treatment with PP or 
HD because they were at risk of efficacy failure due to medication non-compliance and/or 
significant substance abuse. Entry and exclusion criteria have been presented previously 
(11).
Interventions
A total of 353 patients enrolled for screening; 311 were eligible and randomized to study 
treatment (see consort diagram in McEvoy et. al., 2014). Study treatments were long-acting 
injectable PP supplied in dosages of 39 mg, 78 mg, 117 mg, 156 mg and 234 mg; and HD 
supplied in vials of 50 mg/ml or 100 mg/ml for injection. Each participant received a blinded 
trial of the oral version of the assigned medication prior to receiving an injection. The first 
injection was given 4–7 days after the baseline visit. Subsequent visits were at weeks 1, 2, 4, 
6, 8, 10, and 12, then monthly (i.e., every four weeks) for up to 24 months. Altogether 62 
(43%) PP patients completed the 18 month follow-up assessment and 71 (49%) of HD 
patients with no significant difference between groups (chi sq= 0.77, df=6, p=0.94).
Study physicians and all other personnel were blinded to treatment condition. A clinician not 
otherwise involved in the trial administered the injection (11).
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Outcome Measures
The primary outcomes were Quality Adjusted Life Years (QALYs) and total costs from the 
perspective of the healthcare system (12).
Effectiveness—Cost-effectiveness analysis depends having a single measure of health 
related quality of life that addresses health gains as well as losses due to side effects. It is 
recommended that health states be expressed as QALYs, a year of life rated on a cardinal 
scale from 0 (worst possible health) to 1 (perfect health), as evaluated by members of the 
general public (12).
A series of studies has demonstrated a method for evaluating QALYs in schizophrenia (13–
15) based on the Positive and Negative Syndrome Scale (PANSS) (16) and side-effect data. 
The derivation of QALYs from PANSS data began with a cluster analysis of a sample of 
almost 400 patients which identified 8 disease-specific health states. With input from expert 
study clinicians, script and video materials were developed to convey impairments 
experienced with each schizophrenia state, and with five commonly co-occurring adverse 
side effects (orthostatic hypotension, weight gain, tardive dyskinesia, pseudo-parkinsonism 
and akathisia) (13). Using these video presentations, the states were rated by 620 members 
of the general public using the standard gamble, the recommended method for QALY 
determination (12). Responses were weighted to represent the socio-demographic 
characteristics of the adult US population.
Costs—The economic perspective addressed total health care costs (mental health and 
medical health service use plus medications at prices faced by the health care system. the 
perspective used in this study). Service use was assessed through detailed quarterly 
interviews conducted by trained research staff, documenting inpatient and outpatient 
psychiatric and medical health service use. Costs were then estimated by multiplying the 
number of units of each type of service received by the estimated unit cost of that service, 
and then summing the products across difference services.
Evaluation of Service Use and Costs: Monthly service use was documented every three 
months through a self-report questionnaire that recorded four kinds of hospital days 
(medical, surgical, psychiatric, and substance abuse) across six different facility types (e.g. 
state mental hospitals, private psychiatric hospitals, non-federal general hospitals). Nights 
spent in nursing homes and halfway houses were also recorded. Use of 16 types of 
outpatient mental health care, including psychiatric and psycho-social rehabilitation 
services, were documented along with 8 different types of medical or surgical outpatient 
visit, and emergency room services.
Unit costs of these services were estimated from published reports (33–38) and 
administrative data sets (38)(Medicaid, MarketScan® private claims data base, and Veterans 
Health Administration data).
Costs of antipsychotic medications, other psychotropic medications, and non-psychotropic 
medication were based on discounted prices from the Federal Supply Schedule Prices, which 
are the lowest non-generic prices available – the most conservative prices. The unit of 
Rosenheck et al. Page 4
Psychiatr Serv. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analysis for cost-evaluation is the total average health cost per quarter (average monthly 
costs multiplied times 3), including costs of all health service use, study medications at the 
prescribed doses and other prescribed drugs.
Statistical methods
The analytic sample consisted of all patients who received at least one injection and at least 
one post-baseline assessment.
Effectiveness, service use and cost analyses compared treatment groups on average quarterly 
effectiveness and service use (QALYs, hospital or residential days, outpatient visits and 
medications) and related costs across 18 months using a mixed model including terms 
representing treatment group and time (treated as a classification variable for 3, 6, 9, 12, 15, 
and 18 months). A random subject effect and a first-order autoregressive covariance 
structure were used to adjust standard errors for the correlation of observations from the 
same individual.
In addition to the comparison of effectiveness (improvement in QALYs from baseline) and 
costs between treatments, the incremental cost-effectiveness ratio was calculated as the 
difference in benefits divided by the difference in quarterly costs. The uncertainty of 
estimated differences in cost and effectiveness was estimated by non-parametric 
bootstrapping of 5,000 ICER regression replications with replacement (17).
The principal cost-benefit analysis was conducted using the method of net health benefits 
(18). In this approach, a range of estimates for the dollar value of a QALY are multiplied by 
the QALY estimate for each patient at each time point to estimate the monetized value of 
their health status at each observation. Following conventions used in policy making (19, 
20), with more recent academic refinements we use estimates of $0/QALY/year to $600,000/
QALY/year in this sensitivity analysis. This yielded a monetized estimate of health status for 
each patient at each time point.
Monthly health care costs were then subtracted from these estimated health benefits to 
generate an estimate of “net health benefit” for each patient for each month at each of the 
estimated monetary values of a QALY. Mixed model regression analyses of the type 
described above were used to compare mean differences between the groups using monthly 
estimates of net health benefits from all time points and adjusting for time, site, and other 
factors.
Over the past decade, it has been increasingly recognized that policy makers typically have 
to make decisions even when findings do not meet the usual 5% standard of uncertainly and 
that it is important to know the probability that one treatment will be more cost-effective 
than another, even when the uncertainty is greater than the conventional 5% (17). Using the 
method of Hoch et al. (21), we calculate the probability that HD had greater net health 
benefits than PP at each of the estimated monetary values of a QALY. This calculation was 
based on a 1-tailed test based on the p-value associated with the coefficient for the treatment 
variable, representing the significance of differences between the treatments calculated as 
HD-PP, and was computed as 1-p/2 (21). These data allow plotting of a Cost-Effectiveness 
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Acceptability Curve, which illustrates graphically the probability that that HD was more 
cost-effective than PP at each estimated monetary value of a QALY.
Analyses were performed using SAS version 9.3 (SAS Institute, Inc.).
Results
The progress of patients who were screened and randomly assigned to each group was 
presented previously (11). Baseline demographic and clinical characteristics of the 145 PP 
and 145 HD patients in the primary analysis were presented in Table 1 of that paper (11).
Dose
In the initial month of LAI treatment, which included doses on day 1 and day 8, the mean 
dose of PP was 325 mg and of HD 94 mg. Subsequently, the mean monthly dose of PP 
ranged from 129–169 mg and the mean monthly dose of HD ranged from 67–83 mg.
Summary of previously published results
In the primary analysis of the original paper (11), there was no statistically significant 
difference in the time to efficacy failure (49 days for PP vs. 47 days for HD; site stratified 
log rank p=.90; site and baseline PANSS adjusted hazard ratio 0.98, 95% CI=0.65–1.47). On 
average, patients taking PP gained weight progressively over time while those on HD lost 
weight (p<0.001).
Patients taking HD experienced greater increases in Barnes Akathisia Scale (BAS) global 
scores (0.45 (0.31–0.59) for PP vs. 0.73 (0.59–0.87) for HD; p=0.006). There were no 
statistically significant differences in changes in ratings of Parkinsonism measured by the 
Simpson-Angus Extrapyramidal Scale (p=0.34) and decreases in PANSS total scores from 
baseline were not significantly different between groups at each time point.
Quality Adjusted Life Years—Mixed model analysis of QALYs as measured by the 
algorithm described above showed slightly higher scores for PP than HD of .0297 QALYs 
over 18 months (p<.03)(Figure 1).
Costs—Antipsychotic drug costs (Table 1) were $2,213 greater per quarter for the PP 
group than for the HD group (p<.001). There were no significant differences in other 
medication costs. Nor were there any significant differences between treatments in total 
inpatient and outpatient, mental health and medical health services use or related service 
costs (excluding medications)(Table 1). Total health service costs including medications 
(Table 1, Figure 2) were $2,100 greater per quarter for the PP group than for the HD group 
(p<.001).
Cost-Effectiveness/Net Health Benefits—Dividing incremental costs by incremental 
benefits in the bootstrap analysis generated an incremental cost effectiveness ratio of 
$508,241/QALY (95% CI=$122,390–$1,582,711) for PP as compared to HD (Figure 3) with 
98% of observations falling the upper right quadrant of the cost-effectiveness plane, 
indicating greater benefits for PP as well as greater costs.
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Analysis of net health benefits expressed in dollars at each estimated value of a QALY 
showed HD to have a 0.95 probability of being more cost-effective than PP at QALY values 
less than $150,000 and 0.81 of being more cost-effective if QALYs are valued at $300,000 
(Figure 4). The probability that HD is more cost-effective than PP declines steadily at values 
of a QALY greater than $300,000 (Figure 4), and is only 0.50 at $500,000 per QALY and .
44 at $600,000.
Discussion
This study found that, using a disease-specific method to calculate health states measured in 
QALYs for people diagnosed with schizophrenia, treatment with PP resulted in a statistically 
significant but small advantage in health status. However, because PP remains on-patent and 
has relatively high acquisition costs, it is not a cost-effective treatment choice under a wide 
range of estimates of the monetary value of a QALY. This was true even though we used the 
lowest available estimate for the cost of the drug. For example, 117 mg of LAI PP is priced 
at $758 on the Federal Supply Schedule used here, while the published average wholesale 
price was $889 (See website: http://pharmacyservices.utah.edu/bulletins/NDB_214.pdf. 
Accessed July 16, 2015) and on-line retail prices for the same dose range from $1,023 to 
$1,106 (See website: http://www.goodrx.com/paliperidone-palmitate#/?
filterlocation=&coords=&label=Invega+Sustenna&form=syringe&strength=0.75ml+of
+117mg&quantity=1.0&qty-custom= Accessed on July 16, 2015). Our findings thus would 
be sustained under a wide range of 2015 prices for PP although prices are likely to drop 
when generic versions of the drug appear after patent protection runs out in 2017.
Many studies of newer second generation antipsychotics end up with ambiguous findings 
showing that while some side effects are less severe with newtreatments, others are more 
severe. The QALY measure used in this study (13) provides a rational approach to 
combining data on symptoms and major side effects in a single measure. In addition, 
selective inclusion only of individuals judged by their clinicians to be likely to benefit from 
LAI treatment, and therefore most like patients prescribed LAI treatments in real-world 
practice, enhances the study’s external validity.
There has been controversy about what monetary value should be assigned to a QALY in 
cost-benefit analysis. On the one hand some governments have long used a value of $50,000 
as the appropriate value of a QALY for policy making (22). However, this estimate was first 
established in 1982 (20), and, with adjustment for inflation alone its value would have 
reached $117,000 by 2011 when the present study was initiated. A more recent valuation 
based on an empirical estimate of the cost-effectiveness of treatments available in 2003 as 
contrasted with care available in 1950, and on the implicit cost-effectiveness of unsubsidized 
insurance as compared to self-pay care, suggest a range from $183,000–$264,000 per 
QALY. While HD was clearly more likely to be cost-effective than PP at a QALY valuation 
of $50,000 (with .998 probability) and at an inflation-adjusted valuation of $117,000 (.985 
probability) it also had a .94 probability of being more cost-effective at $200,000/QALY (the 
lower bound of the Braithwaite et al estimate) and 0.81 at $300,000/QALY (above the upper 
bound estimate of Braithwaite et al.). The probability that HD was more cost-effective than 
PP only declined at values of $500,000 and $600,000/QALY, far higher than currently 
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accepted values. Thus HD is substantially more likely to be cost-effective than PP at a broad 
range of estimates of the value of a QALY as well as of the cost of PP.
The results of this study are consistent with the one other RCT-based cost-effectiveness 
study of a LAI second generation antipsychotic which found no significantly greater benefit 
for LAI risperidone on multiple measures (8) in comparison with doctor’s choice of oral 
medication, but did find more neurological side effects for the LAI treatment and 
significantly increased drug costs, although the difference in total health care cost, while 7% 
greater, was not statistically significant (23).
While several RCTs have found no benefit of LAI second generation antipsychotics as 
compared to oral antipsychotics (24–27) two studies found positive benefits for LAI 
risperidone (9, 28) and a recent publication found robust benefits for LAI risperidone as 
compared to oral risperidone in patients experiencing their first episode of psychosis (10). 
While evidence of the superiority of second generation antipsychotic LAIs to oral 
medications is mixed, the use of LAIs is still supported by systematic reviews (29, 30) and 
expert panels (31) but the current study is the only RCT to compare the cost-effectiveness of 
first and second generation LAIs.
As several newer LAI antipsychotics are now on the market in the US with high on-patent 
acquisition costs, expenditures on these drugs may rise rapidly. The results of this study 
should encourage consideration of older, less expensive drugs such as haloperidol decanoate. 
Used at moderate dosages in this study, HD’s overall effectiveness and tolerability were only 
slightly worse, as reported here, to that of PP, and it had clear advantages in cost-
effectiveness. When generic versions of the newer LAIs become available, the cost-
effectiveness calculations will undoubtedly change. In the meantime, HD appears from trial 
evidence to be a cost-effective choice. A rational policy might limit use of the more 
expensive LAIs among patients with chronic schizophrenia to those who do not benefit from 
or cannot tolerate HD.
Limitations
Several methodological limitations require comment. The available QALY algorithm has not 
been validated beyond the initial studies and it must be acknowledged that people with 
serious mental illness may have difficulty responding to standard gamble choices, even when 
they are presented using simplified graphic displays. In addition, although the QALY 
responses were weighted using socio-demographic characteristics of the US population, 
QALY values may vary by unmeasured respondent characteristics. Imperfect as this measure 
may be, the results are consistent with those observed on individual measures in the original 
publication from this study (11) and provide a rational empirical basis for assigning 
monetary values to health states.
Second, utilization data were based on patient self-report estimations of service use and 
published estimations of unit costs (i.e. not actual unit costs or verified service use) and 
there were substantial missing data from the study. If, as might be expected due to memory 
lapses, respondents underestimated their service use, actual group differences could have 
been underestimated as well. Missing data was addressed with mixed models using all 
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available data and study drop out rates were similar to those in the NIMH CATIE study (5, 
32) and others, (32) but recall biases can not be ruled out. In spite of these limitations the 
findings of this study appear to be robust to a number of sensitivity analyses representing 
alternative assumptions and methods of analysis.
Conclusion
HD was more cost-effective than PP suggesting that PP’s slightly greater benefits do not 
justify its markedly higher on-patent costs.
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Figure 1. 
Comparison of PP and HD on Quality Adjusted Life Years (QALYs)*
* Average difference = +.0297 favoring paliperidone (p<.03)
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Figure 2. 
Quarterly total outpatient, inpatient and drug costs (p<.003)
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Figure 3. 
Bootstrap analysis of the incremental cost effectiveness ratio (ICER): PP vs. HD
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Figure 4. 
Cost Effectiveness Acceptability Curve (HD>PP)
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